As of 12:49:11 PM EDT. Market Open. CAMBRIDGE, Mass. & SALISBURY, England, April 08, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary ...

Shares of KalVista Pharmaceuticals (NASDAQ:KALV) spiked in the premarket on Tuesday after the company disclosed a licensing agreement with the Japanese drugmaker Kaken Pharmaceutical (OTCPK ...

Short interest in KalVista Pharmaceuticals Inc (NASDAQ:KALV) decreased during the last reporting period, falling from 5.83M to 5.54M. This put 12.66% of the company's publicly available shares short.

Benjamin L Palleiko, the CHIEF EXECUTIVE OFFICER of $KALV, sold 6,669 shares of the company on 03-07-2025 for an estimated $79,827. We received data on the trade from ...

Paul K. Audhya, the CHIEF MEDICAL OFFICER of $KALV, sold 2,394 shares of the company on 02-24-2025 for an estimated $23,987. We received data on the trade from a ...